You are here

Article Text

Article menu
Download PDFPDF
Poster Presentations
SLE, Sjögren's and APS - clinical aspects (other than treatment)
FRI0413 Comorbidity in a Cohort of Primary Sjögren's Syndrome Patients
  1. M. Fernandez Castro1,
  2. J.L. Andreu2,
  3. J. Rosas3,
  4. V. Martínez Taboada4,
  5. A. Olivé5,
  6. C. Sánchez-Piedra6,
  7. R. Menor7,
  8. B. Rodriguez8,
  9. A. García Aparicio9,
  10. F.J. Lόpez Longo10,
  11. S. Manrique-Arija11,
  12. J.A. García Vadillo12,
  13. S. Gil Barato13,
  14. R. Lόpez González14,
  15. F.J. Narváez15,
  16. C. Galisteo16,
  17. J. González Martín17,
  18. E. Ruiz Lucea18,
  19. C. Erausquin19,
  20. C. Guillén Astete20,
  21. I. Castellvi21,
  22. C. Bohόrquez22,
  23. J. Loricera4,
  24. J. Belzunegui23
  25. on behalf of Sjögren's Project, Systemic Autoimmune Disease's Group of the Spanish Rheumatology Society
  1. 1Hospital Infanta Sofía
  2. 2Hospital Puerta de Hierro, Madrid
  3. 3Hospital de Marina Baixa, Villajoyosa
  4. 4Hospital Marqués de Valdecilla, Santander
  5. 5Hospital Germans Trias i Pujol, Badalona
  6. 6Spanish Rheumatology Society's Research Unit, Madrid
  7. 7Hospital General Jerez de la Frontera, Jerez de la Frontera
  8. 8Hospital Universitario de Canarias, Santa Cruz de Tenerife
  9. 9Hospital Virgen de la Salud, Toledo
  10. 10Hospital Gregorio Marañόn, Madrid
  11. 11Hospital Carlos Haya, Málaga
  12. 12Hospital de la Princesa, Madrid
  13. 13Hospital General de Alicante, Alicante
  14. 14Hospital Virgen de la Concha, Zamora
  15. 15Hospital de Bellvitge, Barcelona
  16. 16Hospital Parc-Taulí, Sabadell
  17. 17Hospital Madrid Norte Sanchinarro, Madrid
  18. 18Hospital de Basurto, Basurto
  19. 19Hospital Doctor Negrín, Las Palmas de Gran Canarias
  20. 20Hospital Ramόn y Cajal, Madrid
  21. 21Hospital San Pau y Santa Creu, Barcelona
  22. 22Hospital Príncipe de Asturias, Alcalá de Henares
  23. 23Hospital de Donostia, Gipuzkoa, Spain

Abstract

Background Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune disease with a substantial impact on patient's quality of life and associated comorbidities could worsen the prognosis and complicate the management of the disease.

Objectives The aim of our study was to describe comorbidities in a Spanish cohort os pSS patients.

Methods We took advantage of a multicenter descriptive transversal study of a cohort of pSS patients fulfilling European/American criteria. It is a randomised register of patients obtained from thirty three Reumathology clinics all over Spain. The presence of comorbidities was investigated in every patient. Previous informed consent was obtained and local ethics committees approved the study. Variables were analysed by descriptive statistical methods, using means, medians, and rates, with their deviations and interquartile ranges (p25-p75).

Results A total of 437 patients were included, 95% of them women, with a median age of 58 years. Dyslipidemia was the most common comorbidity, appearing in 33% of the cases, with hypertension in second place with a prevalence of 25%. Osteoporosis was present in 18% of patients. Furthermore, 37 patients had at least an osteoporotic fracture. Seventy four patients had never smoked. Diabetes was present in 6% of cases. Less than 7% of the patients had some kind of cardiovascular event: 4 patients ischemic heart disease, 14 patients peripheral arterial disease and 15 patients strokes. Among patients with peripheral arterial disease, only one patient showed positive anti phospholipid antibodies. Thirteen patients (3%) had heart failure. Sixty four patients (14%) had fibromyalgia. Five patients (1%) had celiac disease and 2 (0.46%), multiple sclerosis. Seven lymphomas were observed, four of them MALT type and two Hogdkin's disease. Three patients developed multiple myeloma and two Waldenstrom's macroglobulinemia. Twenty one cases of other malignancy were registered.

Conclusions Primary Sjögren's syndrome's patients frequently present associated comorbidities, been dyslipidemia, arterial hypertension and osteoporosis the most prevalent. Lymphoma prevalence rate for this series is 1,6 percent.

Disclosure of Interest None declared

https://doi.org/10.1136/annrheumdis-2015-eular.2597

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.